Cargando…

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer

Non-small cell lung cancer negative for actionable molecular markers entered the splendid era of immunotherapy. This review aims to provide an evidence-based summary for immunotherapy for unresectable locally advanced non-small cell lung cancer, and references for clinical strategies of immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaofei, Zhang, Jianguo, Liu, Peiyi, Wang, Juan, Zhao, Kuaile, Zhu, Zhengfei, Gu, Kangsheng, Zhao, Weixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945126/
https://www.ncbi.nlm.nih.gov/pubmed/36845690
http://dx.doi.org/10.3389/fonc.2023.1022042
_version_ 1784892072682061824
author Zhang, Xiaofei
Zhang, Jianguo
Liu, Peiyi
Wang, Juan
Zhao, Kuaile
Zhu, Zhengfei
Gu, Kangsheng
Zhao, Weixin
author_facet Zhang, Xiaofei
Zhang, Jianguo
Liu, Peiyi
Wang, Juan
Zhao, Kuaile
Zhu, Zhengfei
Gu, Kangsheng
Zhao, Weixin
author_sort Zhang, Xiaofei
collection PubMed
description Non-small cell lung cancer negative for actionable molecular markers entered the splendid era of immunotherapy. This review aims to provide an evidence-based summary for immunotherapy for unresectable locally advanced non-small cell lung cancer, and references for clinical strategies of immunotherapy. Through literature review, the standard treatment for unresectable locally advanced non-small cell lung cancer should be radical concurrent radiotherapy and chemotherapy followed by consolidation immunotherapy. However, the efficacy of concurrent radiotherapy, chemotherapy combined with immunotherapy has not been improved, and its safety should be further validated. It is believed that induction immunotherapy plus concurrent radiotherapy and chemotherapy plus consolidation immunotherapy is promising. In clinical practice, the delineation of radiotherapy target should be relatively small. Pemetrexed combined with PD-1 inhibitor induces the strongest immunogenicity in chemotherapy, which is suggested by preclinical pathway study. Although there is no significant difference between PD1 and PD1 for effect, PD-L1 inhibitor is better in the combination treatment of radiotherapy which presents significantly less adverse events.
format Online
Article
Text
id pubmed-9945126
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99451262023-02-23 Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer Zhang, Xiaofei Zhang, Jianguo Liu, Peiyi Wang, Juan Zhao, Kuaile Zhu, Zhengfei Gu, Kangsheng Zhao, Weixin Front Oncol Oncology Non-small cell lung cancer negative for actionable molecular markers entered the splendid era of immunotherapy. This review aims to provide an evidence-based summary for immunotherapy for unresectable locally advanced non-small cell lung cancer, and references for clinical strategies of immunotherapy. Through literature review, the standard treatment for unresectable locally advanced non-small cell lung cancer should be radical concurrent radiotherapy and chemotherapy followed by consolidation immunotherapy. However, the efficacy of concurrent radiotherapy, chemotherapy combined with immunotherapy has not been improved, and its safety should be further validated. It is believed that induction immunotherapy plus concurrent radiotherapy and chemotherapy plus consolidation immunotherapy is promising. In clinical practice, the delineation of radiotherapy target should be relatively small. Pemetrexed combined with PD-1 inhibitor induces the strongest immunogenicity in chemotherapy, which is suggested by preclinical pathway study. Although there is no significant difference between PD1 and PD1 for effect, PD-L1 inhibitor is better in the combination treatment of radiotherapy which presents significantly less adverse events. Frontiers Media S.A. 2023-02-08 /pmc/articles/PMC9945126/ /pubmed/36845690 http://dx.doi.org/10.3389/fonc.2023.1022042 Text en Copyright © 2023 Zhang, Zhang, Liu, Wang, Zhao, Zhu, Gu and Zhao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Xiaofei
Zhang, Jianguo
Liu, Peiyi
Wang, Juan
Zhao, Kuaile
Zhu, Zhengfei
Gu, Kangsheng
Zhao, Weixin
Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
title Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
title_full Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
title_fullStr Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
title_full_unstemmed Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
title_short Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
title_sort immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945126/
https://www.ncbi.nlm.nih.gov/pubmed/36845690
http://dx.doi.org/10.3389/fonc.2023.1022042
work_keys_str_mv AT zhangxiaofei immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer
AT zhangjianguo immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer
AT liupeiyi immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer
AT wangjuan immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer
AT zhaokuaile immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer
AT zhuzhengfei immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer
AT gukangsheng immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer
AT zhaoweixin immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer